Literature DB >> 16482446

Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies.

Lorenz Grigull1, Andreas Beilken, Hansjoerg Schmid, P Kirschner, Karl-Walter Sykora, Christin Linderkamp, Frank Donnerstag, Lilia Goudeva, Hans-Gert Heuft, Karl Welte.   

Abstract

Fungal infections represent a life-threatening complication for patients receiving chemotherapy or undergoing hematopoietic stem cell transplantation. Historically, antifungal monotherapy is associated with a poor outcome. We treated three children with hematological malignancies and proven fungal infections (one cerebral mold infection, one disseminated Candida infection, one naso-pharyngeal mucor infection) with combination antifungal therapy plus granulocyte-colony-stimulation-factor-mobilized granulocyte transfusions as secondary prophylaxis during subsequent neutropenic episodes. With this approach, the fungal infection was effectively treated, and the anticancer therapy was completed without major delay. All children survived the fungal infection and the underlying malignancy. These experiences illustrate the feasibility of this approach using more than one antifungal agent together with immune-therapy in high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16482446     DOI: 10.1007/s00520-005-0910-8

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  13 in total

1.  Efficacy and safety of G-CSF mobilized granulocyte transfusions in four neutropenic children with sepsis and invasive fungal infection.

Authors:  L Grigull; A Schrauder; A Schmitt-Thomssen; K Sykora; K Welte
Journal:  Infection       Date:  2002-10       Impact factor: 3.553

Review 2.  Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Drug Resist Updat       Date:  2003-10       Impact factor: 18.500

3.  The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation.

Authors:  J Paul Kerr; Effie Liakopolou; Jessica Brown; Jacqueline M Cornish; David Fleming; Edwin Massey; Anthony Oakhill; Derwood H Pamphilon; Stephen P Robinson; April Totem; Alexandra M P I Valencia; David I Marks
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

Review 4.  Immunomodulation of invasive fungal infections.

Authors:  Emmanuel Roilides; Caron A Lyman; Paraskevi Panagopoulou; Stephen Chanock
Journal:  Infect Dis Clin North Am       Date:  2003-03       Impact factor: 5.982

5.  Antifungal therapy in patients with fever and neutropenia--more rational and less empirical?

Authors:  Jean Klastersky
Journal:  N Engl J Med       Date:  2004-09-30       Impact factor: 91.245

Review 6.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 7.  New agents for invasive mycoses in children.

Authors:  Charalampos Antachopoulos; Thomas J Walsh
Journal:  Curr Opin Pediatr       Date:  2005-02       Impact factor: 2.856

8.  Treatment and outcome of invasive Aspergillus infections in allogeneic BMT recipients.

Authors:  E Jantunen; P Ruutu; A Piilonen; L Volin; T Parkkali; T Ruutu
Journal:  Bone Marrow Transplant       Date:  2000-10       Impact factor: 5.483

9.  Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.

Authors:  Cheol-In Kang; Sung-Han Kim; Wan Beom Park; Ki-Deok Lee; Hong-Bin Kim; Eui-Chong Kim; Myoung-Don Oh; Kang-Won Choe
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

10.  High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study.

Authors:  H A Torres; D P Kontoyiannis; K V I Rolston
Journal:  Support Care Cancer       Date:  2004-02-19       Impact factor: 3.603

View more
  18 in total

1.  Does granulocyte transfusion play a role in the multidisciplinary treatment of invasive mycosis?

Authors:  Simone Cesaro; Piero Marson
Journal:  Support Care Cancer       Date:  2006-10-12       Impact factor: 3.603

Review 2.  Granulocyte transfusions: A concise review for practitioners.

Authors:  Juan Gea-Banacloche
Journal:  Cytotherapy       Date:  2017-09-12       Impact factor: 5.414

Review 3.  Th17 cells in immunity to Candida albicans.

Authors:  Nydiaris Hernández-Santos; Sarah L Gaffen
Journal:  Cell Host Microbe       Date:  2012-05-17       Impact factor: 21.023

4.  Changing Trends in the Use of Granulocyte Transfusions in Neutropenic Children with Sepsis in India.

Authors:  Ramya Uppuluri; Sreejith Ramachandrakurup; Lakshman Vaidhyanathan; Sathishkumar Kandath; Divya Subburaj; Revathi Raj
Journal:  Indian J Hematol Blood Transfus       Date:  2016-09-26       Impact factor: 0.900

Review 5.  Human Fungal Pathogens of Mucorales and Entomophthorales.

Authors:  Leonel Mendoza; Raquel Vilela; Kerstin Voelz; Ashraf S Ibrahim; Kerstin Voigt; Soo Chan Lee
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-06       Impact factor: 6.915

Review 6.  Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropenia.

Authors:  Mohan Pammi; Peter Brocklehurst
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

7.  Recent advances in the treatment of mucormycosis.

Authors:  Brad Spellberg; Ashraf S Ibrahim
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

Review 8.  Invasive fungal infections: the challenge continues.

Authors:  Antonino Gullo
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Pulmonary mucormycosis: what is the best strategy for therapy?

Authors:  Juan F Fernandez; Diego J Maselli; Tamara Simpson; Marcos I Restrepo
Journal:  Respir Care       Date:  2013-05       Impact factor: 2.258

Review 10.  Recent advances in the management of mucormycosis: from bench to bedside.

Authors:  Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis; John Edwards; Ashraf S Ibrahim
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.